Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study
Autistic disorder is a neuropsychiatric syndrome characterized by deficits in social interaction; qualitative impairments in communication; and restricted, repetitive, and stereotyped patterns of behavior, interests, or activities. It is classified as a type of pervasive developmental disorder (PDD)...
Gespeichert in:
Veröffentlicht in: | Journal of child and adolescent psychopharmacology 2013-06, Vol.23 (5), p.329-336 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 336 |
---|---|
container_issue | 5 |
container_start_page | 329 |
container_title | Journal of child and adolescent psychopharmacology |
container_volume | 23 |
creator | Wake, Rei Miyaoka, Tsuyoshi Inagaki, Takuji Furuya, Motohide Ieda, Masa Liaury, Kristian Kishi, Kazuko Horiguchi, Jun |
description | Autistic disorder is a neuropsychiatric syndrome characterized by deficits in social interaction; qualitative impairments in communication; and restricted, repetitive, and stereotyped patterns of behavior, interests, or activities. It is classified as a type of pervasive developmental disorder (PDD). All PDDs have a qualitative impairment in social relatedness. However, many individuals with PDDs have interfering symptoms, including irritability (aggression, self-injurious behavior, and severe tantrums). Behavioral therapy is often helpful in decreasing these behaviors; however, sometimes adjunctive medications are needed, because of the intensity and severity of irritability. Numerous medications have been tested on patients with PDDs. Although many of these medications have been demonstrated to be useful, no clear main treatment for PDD has emerged. Despite the efficacy of some of the medicines, acceptability and side effects have proven to be barriers to their use. Yokukansan (TJ-54), a traditional Japanese medicine, is composed of seven kinds of dried herbs. It is widely prescribed in clinical situations for treating psychiatric disorders by acting mainly on the glutamatergic and serotonergic nervous system. Recent studies indicate that TJ-54 may be safe and useful in treating behavioral and psychological symptoms in dementia patients. We aimed at evaluating both the efficacy and the safety of TJ-54 in patients with PDDs.
This was a 12 week prospective, open-label investigation of TJ-54 in 20 children and adolescents ages 6-17 years diagnosed with PDDs. Primary outcome measures included the Clinical Global Impressions-Improvement of Illness Scale (CGI-I), Children's Global Assessment Score (CGAS), and the Aberrant Behavior Checklist (ABC) irritability subscale.
Twenty subjects, ages 6-17 years, received TJ-54 in the dosage range of 2.5-7.5 g/day. The CGI-I was significantly improved from 8 weeks (p |
doi_str_mv | 10.1089/cap.2012.0108 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1370634832</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1370634832</sourcerecordid><originalsourceid>FETCH-LOGICAL-c321t-24ccc95446305c136110b3d20d39c1d70441d08ab58b50cd6ba7e443fa10de953</originalsourceid><addsrcrecordid>eNpdkUlvFDEQhS0EIgscuUaWuASJHrz0yg1FhEWRuIQDp1a1XaM447E7tnui-Sn8W2qU5cCpXNLnp_fqMfZOipUU_fDJwLxSQqqVoPUFO5ZN01X9MKiX9BZ1XTV1q4_YSc63QkjdivY1O1K665VU3TH7-ydulg2EDIGfX_8k-gNfx8RdSq7A5Lwrew45R-OgoOX3rtzwGdMOstsht7hDH-cthgKeW5djski_Azc3ztuEgUOwHGz0mA1R-TMHLlV1j7jhc4p5RlNI6SOPM4bKw4Se57LY_Rv2ag0-49vHecp-X369vvheXf369uPiy1VltJKlUrUxZmhqSikaQwGlFJO2Slg9GGk7OoG0ooep6adGGNtO0GFd6zVIYXFo9Ck7f9AlN3cL5jJuHVn1HgLGJY9Sd6LVda8Voe__Q2_jkgK5I6odtNC67YmqHihD8XLC9Tgnt4W0H6UYD52N1Nl46Gw8dEb82aPqMm3RPtNPJel_aKSS5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1369303368</pqid></control><display><type>article</type><title>Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Wake, Rei ; Miyaoka, Tsuyoshi ; Inagaki, Takuji ; Furuya, Motohide ; Ieda, Masa ; Liaury, Kristian ; Kishi, Kazuko ; Horiguchi, Jun</creator><creatorcontrib>Wake, Rei ; Miyaoka, Tsuyoshi ; Inagaki, Takuji ; Furuya, Motohide ; Ieda, Masa ; Liaury, Kristian ; Kishi, Kazuko ; Horiguchi, Jun</creatorcontrib><description>Autistic disorder is a neuropsychiatric syndrome characterized by deficits in social interaction; qualitative impairments in communication; and restricted, repetitive, and stereotyped patterns of behavior, interests, or activities. It is classified as a type of pervasive developmental disorder (PDD). All PDDs have a qualitative impairment in social relatedness. However, many individuals with PDDs have interfering symptoms, including irritability (aggression, self-injurious behavior, and severe tantrums). Behavioral therapy is often helpful in decreasing these behaviors; however, sometimes adjunctive medications are needed, because of the intensity and severity of irritability. Numerous medications have been tested on patients with PDDs. Although many of these medications have been demonstrated to be useful, no clear main treatment for PDD has emerged. Despite the efficacy of some of the medicines, acceptability and side effects have proven to be barriers to their use. Yokukansan (TJ-54), a traditional Japanese medicine, is composed of seven kinds of dried herbs. It is widely prescribed in clinical situations for treating psychiatric disorders by acting mainly on the glutamatergic and serotonergic nervous system. Recent studies indicate that TJ-54 may be safe and useful in treating behavioral and psychological symptoms in dementia patients. We aimed at evaluating both the efficacy and the safety of TJ-54 in patients with PDDs.
This was a 12 week prospective, open-label investigation of TJ-54 in 20 children and adolescents ages 6-17 years diagnosed with PDDs. Primary outcome measures included the Clinical Global Impressions-Improvement of Illness Scale (CGI-I), Children's Global Assessment Score (CGAS), and the Aberrant Behavior Checklist (ABC) irritability subscale.
Twenty subjects, ages 6-17 years, received TJ-54 in the dosage range of 2.5-7.5 g/day. The CGI-I was significantly improved from 8 weeks (p<0.001). The mean CGAS was 31.92 at baseline, whereas the mean final score at 12 weeks was 54.52 (p<0.001). The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks. TJ-54 was well tolerated. No subject left the study because of a drug-related adverse event.
These preliminary data suggest that TJ-54 may be effective and well tolerated for the treatment of severe irritability/agitation and hyperactivity/noncompliance in children and adolescents ages 6-17 years with PDD. However, given the characteristics of this trial, the present findings should be taken cautiously, and larger-scale placebo-controlled studies are needed to elucidate the efficacy and tolerability of TJ-54 in this understudied population.</description><identifier>ISSN: 1044-5463</identifier><identifier>EISSN: 1557-8992</identifier><identifier>DOI: 10.1089/cap.2012.0108</identifier><identifier>PMID: 23782127</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adolescent ; Autism ; Child ; Child Development Disorders, Pervasive - drug therapy ; Child Development Disorders, Pervasive - physiopathology ; Children & youth ; Drugs, Chinese Herbal - adverse effects ; Drugs, Chinese Herbal - therapeutic use ; Female ; Follow-Up Studies ; Herbal medicine ; Humans ; Irritable Mood - drug effects ; Male ; Pilot Projects ; Prospective Studies ; Psychiatric Status Rating Scales ; Severity of Illness Index ; Time Factors ; Treatment Outcome</subject><ispartof>Journal of child and adolescent psychopharmacology, 2013-06, Vol.23 (5), p.329-336</ispartof><rights>(©) Copyright 2013, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c321t-24ccc95446305c136110b3d20d39c1d70441d08ab58b50cd6ba7e443fa10de953</citedby><cites>FETCH-LOGICAL-c321t-24ccc95446305c136110b3d20d39c1d70441d08ab58b50cd6ba7e443fa10de953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23782127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wake, Rei</creatorcontrib><creatorcontrib>Miyaoka, Tsuyoshi</creatorcontrib><creatorcontrib>Inagaki, Takuji</creatorcontrib><creatorcontrib>Furuya, Motohide</creatorcontrib><creatorcontrib>Ieda, Masa</creatorcontrib><creatorcontrib>Liaury, Kristian</creatorcontrib><creatorcontrib>Kishi, Kazuko</creatorcontrib><creatorcontrib>Horiguchi, Jun</creatorcontrib><title>Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study</title><title>Journal of child and adolescent psychopharmacology</title><addtitle>J Child Adolesc Psychopharmacol</addtitle><description>Autistic disorder is a neuropsychiatric syndrome characterized by deficits in social interaction; qualitative impairments in communication; and restricted, repetitive, and stereotyped patterns of behavior, interests, or activities. It is classified as a type of pervasive developmental disorder (PDD). All PDDs have a qualitative impairment in social relatedness. However, many individuals with PDDs have interfering symptoms, including irritability (aggression, self-injurious behavior, and severe tantrums). Behavioral therapy is often helpful in decreasing these behaviors; however, sometimes adjunctive medications are needed, because of the intensity and severity of irritability. Numerous medications have been tested on patients with PDDs. Although many of these medications have been demonstrated to be useful, no clear main treatment for PDD has emerged. Despite the efficacy of some of the medicines, acceptability and side effects have proven to be barriers to their use. Yokukansan (TJ-54), a traditional Japanese medicine, is composed of seven kinds of dried herbs. It is widely prescribed in clinical situations for treating psychiatric disorders by acting mainly on the glutamatergic and serotonergic nervous system. Recent studies indicate that TJ-54 may be safe and useful in treating behavioral and psychological symptoms in dementia patients. We aimed at evaluating both the efficacy and the safety of TJ-54 in patients with PDDs.
This was a 12 week prospective, open-label investigation of TJ-54 in 20 children and adolescents ages 6-17 years diagnosed with PDDs. Primary outcome measures included the Clinical Global Impressions-Improvement of Illness Scale (CGI-I), Children's Global Assessment Score (CGAS), and the Aberrant Behavior Checklist (ABC) irritability subscale.
Twenty subjects, ages 6-17 years, received TJ-54 in the dosage range of 2.5-7.5 g/day. The CGI-I was significantly improved from 8 weeks (p<0.001). The mean CGAS was 31.92 at baseline, whereas the mean final score at 12 weeks was 54.52 (p<0.001). The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks. TJ-54 was well tolerated. No subject left the study because of a drug-related adverse event.
These preliminary data suggest that TJ-54 may be effective and well tolerated for the treatment of severe irritability/agitation and hyperactivity/noncompliance in children and adolescents ages 6-17 years with PDD. However, given the characteristics of this trial, the present findings should be taken cautiously, and larger-scale placebo-controlled studies are needed to elucidate the efficacy and tolerability of TJ-54 in this understudied population.</description><subject>Adolescent</subject><subject>Autism</subject><subject>Child</subject><subject>Child Development Disorders, Pervasive - drug therapy</subject><subject>Child Development Disorders, Pervasive - physiopathology</subject><subject>Children & youth</subject><subject>Drugs, Chinese Herbal - adverse effects</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Herbal medicine</subject><subject>Humans</subject><subject>Irritable Mood - drug effects</subject><subject>Male</subject><subject>Pilot Projects</subject><subject>Prospective Studies</subject><subject>Psychiatric Status Rating Scales</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1044-5463</issn><issn>1557-8992</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkUlvFDEQhS0EIgscuUaWuASJHrz0yg1FhEWRuIQDp1a1XaM447E7tnui-Sn8W2qU5cCpXNLnp_fqMfZOipUU_fDJwLxSQqqVoPUFO5ZN01X9MKiX9BZ1XTV1q4_YSc63QkjdivY1O1K665VU3TH7-ydulg2EDIGfX_8k-gNfx8RdSq7A5Lwrew45R-OgoOX3rtzwGdMOstsht7hDH-cthgKeW5djski_Azc3ztuEgUOwHGz0mA1R-TMHLlV1j7jhc4p5RlNI6SOPM4bKw4Se57LY_Rv2ag0-49vHecp-X369vvheXf369uPiy1VltJKlUrUxZmhqSikaQwGlFJO2Slg9GGk7OoG0ooep6adGGNtO0GFd6zVIYXFo9Ck7f9AlN3cL5jJuHVn1HgLGJY9Sd6LVda8Voe__Q2_jkgK5I6odtNC67YmqHihD8XLC9Tgnt4W0H6UYD52N1Nl46Gw8dEb82aPqMm3RPtNPJel_aKSS5w</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Wake, Rei</creator><creator>Miyaoka, Tsuyoshi</creator><creator>Inagaki, Takuji</creator><creator>Furuya, Motohide</creator><creator>Ieda, Masa</creator><creator>Liaury, Kristian</creator><creator>Kishi, Kazuko</creator><creator>Horiguchi, Jun</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7RV</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201306</creationdate><title>Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study</title><author>Wake, Rei ; Miyaoka, Tsuyoshi ; Inagaki, Takuji ; Furuya, Motohide ; Ieda, Masa ; Liaury, Kristian ; Kishi, Kazuko ; Horiguchi, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c321t-24ccc95446305c136110b3d20d39c1d70441d08ab58b50cd6ba7e443fa10de953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Autism</topic><topic>Child</topic><topic>Child Development Disorders, Pervasive - drug therapy</topic><topic>Child Development Disorders, Pervasive - physiopathology</topic><topic>Children & youth</topic><topic>Drugs, Chinese Herbal - adverse effects</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Herbal medicine</topic><topic>Humans</topic><topic>Irritable Mood - drug effects</topic><topic>Male</topic><topic>Pilot Projects</topic><topic>Prospective Studies</topic><topic>Psychiatric Status Rating Scales</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wake, Rei</creatorcontrib><creatorcontrib>Miyaoka, Tsuyoshi</creatorcontrib><creatorcontrib>Inagaki, Takuji</creatorcontrib><creatorcontrib>Furuya, Motohide</creatorcontrib><creatorcontrib>Ieda, Masa</creatorcontrib><creatorcontrib>Liaury, Kristian</creatorcontrib><creatorcontrib>Kishi, Kazuko</creatorcontrib><creatorcontrib>Horiguchi, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of child and adolescent psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wake, Rei</au><au>Miyaoka, Tsuyoshi</au><au>Inagaki, Takuji</au><au>Furuya, Motohide</au><au>Ieda, Masa</au><au>Liaury, Kristian</au><au>Kishi, Kazuko</au><au>Horiguchi, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study</atitle><jtitle>Journal of child and adolescent psychopharmacology</jtitle><addtitle>J Child Adolesc Psychopharmacol</addtitle><date>2013-06</date><risdate>2013</risdate><volume>23</volume><issue>5</issue><spage>329</spage><epage>336</epage><pages>329-336</pages><issn>1044-5463</issn><eissn>1557-8992</eissn><abstract>Autistic disorder is a neuropsychiatric syndrome characterized by deficits in social interaction; qualitative impairments in communication; and restricted, repetitive, and stereotyped patterns of behavior, interests, or activities. It is classified as a type of pervasive developmental disorder (PDD). All PDDs have a qualitative impairment in social relatedness. However, many individuals with PDDs have interfering symptoms, including irritability (aggression, self-injurious behavior, and severe tantrums). Behavioral therapy is often helpful in decreasing these behaviors; however, sometimes adjunctive medications are needed, because of the intensity and severity of irritability. Numerous medications have been tested on patients with PDDs. Although many of these medications have been demonstrated to be useful, no clear main treatment for PDD has emerged. Despite the efficacy of some of the medicines, acceptability and side effects have proven to be barriers to their use. Yokukansan (TJ-54), a traditional Japanese medicine, is composed of seven kinds of dried herbs. It is widely prescribed in clinical situations for treating psychiatric disorders by acting mainly on the glutamatergic and serotonergic nervous system. Recent studies indicate that TJ-54 may be safe and useful in treating behavioral and psychological symptoms in dementia patients. We aimed at evaluating both the efficacy and the safety of TJ-54 in patients with PDDs.
This was a 12 week prospective, open-label investigation of TJ-54 in 20 children and adolescents ages 6-17 years diagnosed with PDDs. Primary outcome measures included the Clinical Global Impressions-Improvement of Illness Scale (CGI-I), Children's Global Assessment Score (CGAS), and the Aberrant Behavior Checklist (ABC) irritability subscale.
Twenty subjects, ages 6-17 years, received TJ-54 in the dosage range of 2.5-7.5 g/day. The CGI-I was significantly improved from 8 weeks (p<0.001). The mean CGAS was 31.92 at baseline, whereas the mean final score at 12 weeks was 54.52 (p<0.001). The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks. TJ-54 was well tolerated. No subject left the study because of a drug-related adverse event.
These preliminary data suggest that TJ-54 may be effective and well tolerated for the treatment of severe irritability/agitation and hyperactivity/noncompliance in children and adolescents ages 6-17 years with PDD. However, given the characteristics of this trial, the present findings should be taken cautiously, and larger-scale placebo-controlled studies are needed to elucidate the efficacy and tolerability of TJ-54 in this understudied population.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>23782127</pmid><doi>10.1089/cap.2012.0108</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1044-5463 |
ispartof | Journal of child and adolescent psychopharmacology, 2013-06, Vol.23 (5), p.329-336 |
issn | 1044-5463 1557-8992 |
language | eng |
recordid | cdi_proquest_miscellaneous_1370634832 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Adolescent Autism Child Child Development Disorders, Pervasive - drug therapy Child Development Disorders, Pervasive - physiopathology Children & youth Drugs, Chinese Herbal - adverse effects Drugs, Chinese Herbal - therapeutic use Female Follow-Up Studies Herbal medicine Humans Irritable Mood - drug effects Male Pilot Projects Prospective Studies Psychiatric Status Rating Scales Severity of Illness Index Time Factors Treatment Outcome |
title | Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T23%3A00%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Yokukansan%20(TJ-54)%20for%20irritability%20associated%20with%20pervasive%20developmental%20disorder%20in%20children%20and%20adolescents:%20a%2012-week%20prospective,%20open-label%20study&rft.jtitle=Journal%20of%20child%20and%20adolescent%20psychopharmacology&rft.au=Wake,%20Rei&rft.date=2013-06&rft.volume=23&rft.issue=5&rft.spage=329&rft.epage=336&rft.pages=329-336&rft.issn=1044-5463&rft.eissn=1557-8992&rft_id=info:doi/10.1089/cap.2012.0108&rft_dat=%3Cproquest_cross%3E1370634832%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1369303368&rft_id=info:pmid/23782127&rfr_iscdi=true |